Hepatitis B and NAFLD: Lives Crossed.

Area of Science:

• Hepatology
• Virology
• Metabolic Diseases

Background:

• Hepatitis B virus (HBV) infection is linked to reduced non-alcoholic fatty liver disease (NAFLD) and insulin resistance.
• Metabolic syndrome (MetS) presents a potential risk for advanced liver disease, including cirrhosis and hepatocellular carcinoma, in individuals with chronic hepatitis B.
• Hepatitis B surface antigen (HBsAg) seroclearance, which increases over time, may confound the analysis of NAFLD and HBV prevalence.

Purpose of the Study:

• To investigate the complex interplay between Hepatitis B virus infection, non-alcoholic fatty liver disease, and metabolic syndrome.
• To assess the impact of metabolic syndrome on the progression of liver disease in hepatitis B patients.
• To evaluate the influence of HBsAg seroclearance as a potential confounding factor in epidemiological studies.

Main Methods:

• Epidemiological analysis of patient cohorts with Hepatitis B virus infection.
• Assessment of non-alcoholic fatty liver disease and metabolic syndrome markers.
• Longitudinal evaluation of HBsAg seroclearance rates and their correlation with disease outcomes.

Main Results:

• HBV infection appears to confer protection against steatosis and insulin resistance, potentially decreasing NAFLD prevalence.
• Metabolic syndrome is associated with an elevated risk of disease progression to cirrhosis and liver cancer in hepatitis B patients.
• An increasing trend in HBsAg seroclearance over time was observed, highlighting its role as a potential confounder.

Conclusions:

• The relationship between HBV, NAFLD, and metabolic syndrome is multifaceted, with potential protective effects of HBV against NAFLD but increased risks from metabolic syndrome.
• Understanding the impact of metabolic syndrome and HBsAg seroclearance is crucial for accurate assessment and management of liver disease in hepatitis B patients.